Nipradilol(K‐351)単回経口投与の抗労作狭心症効果持続性の臨床評価  経時的多段階Treadmill運動試験による検討

書誌事項

タイトル別名
  • Clinical evaluation of antianginal effect of nipradilol (K-351) with serial multistage treadmill exercise testing.
  • 経時的多段階Treadmill運動試験による検討

この論文をさがす

抄録

In order to investigate the effects of nipradilol on exercise tolerance, a placebocontrolled study was carried out in 12 patients with stable effort angina pectoris . Multistage treadmill exercise testing was performed before, and at 2, 4, and 7 hours after a single oral administration of placebo at 9: 30 to 10: 00 am . Two to seven days later, the exercise test was again performed with a single oral dose of 6mg nipradilol according to the identical test protocol. In 7 out of 12 patients, treadmill exercise testing was further performed before and 2 hours after a single oral dose of 40mg propranolol. The exercise testing was terminated at moderate anginal pain.<BR>Before administration, there were no significant differences in treadmill exercise duration, heart rate, systolic blood pressure or ST deviation between nipradilol and placebo. At 2, 4, and 7 hours after the administration, the exercise duration was significantly longer after nipradilol than after placebo. However, there were no significant differences in ST deviation at peak exercise between nipradilol and placebo.<BR>Heart rate and systolic blood pressure at rest and systolic blood pressure at peak exercise were significantly reduced or tended to be reduced after nipradilol when compared with placebo.<BR>In 7 patients, there were no significant differences in treadmill exercise duration, heart rate, systolic blood pressure, or ST deviation between nipradilol and propranolol.<BR>These results indicate that nipradilol significantly increases erercise tolerance in patients with stable effort angina pectoris even at 7 hours after a single oral administration mainly due to the decrease in myocardial oxygen demand by beta-blocking action.

収録刊行物

  • 臨床薬理

    臨床薬理 17 (3), 527-540, 1986

    一般社団法人 日本臨床薬理学会

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ